Pharmaceutical Executive: August 2023

Five industry experts discuss labeling challenges and trends in modernization.

From public defender to spearheading the adoption of innovative drugs, Wendy Short Bartie, senior VP and general manager for the hematology and cell therapy division at Bristol Myers Squibb, has remained a steadfast patient advocate—working to fulfill unmet medical needs and bring treatments to as many people as possible.

Now with a seat at the table, growing accountability, and evolving competencies, medical affairs can use its far-reaching influence to change pharma for the better.

Life sciences executives who are confronted by too many choices in launching their environmental, social, and governance programs can leverage these two foundational tools to hone in on the set of issues, actions, and disclosures they should prioritize to create value.

How pharma medical affairs and commercial teams are synchronizing their capabilities to boost omnichannel marketing strategies and better understand customer engagement needs.

The application of artificial intelligence is steadily finding a home in the pharma industry, but these tools may have unprecedented potential in a more nascent niche along the life sciences continuum: drug development.

Could the sector be nearing a turning point in performance?

Drug access leads list of issues raised by pharma shareholders.

Report on lessons from crisis includes—and ignites—some criticism.

Biopharma has a responsibility to meet patients where they are.

Recent lawsuits are challenging the constitutionality of provisions in the Inflation Reduction Act.

Here at Pharmaceutical Executive®, we are already planning our editorial calendar for 2024. And each year we go through this process, I consider this a time of reflection to see where the industry has come, what topics always seem to be on the tips of everyone’s tongues, and what should be a topic of focus. Along with artificial intelligence (AI) being top of mind, other topics that come into my inbox again and again relate to diversity, equity, and inclusion (DE&I) and addressing unmet medical needs.

Click the title above for a link to open the Pharmaceutical Executive August 2023 issue in an interactive PDF format.